LEADER 01620nam  2200457   450 
001 9910707237103321
005 20160622105925.0
035   $a(CKB)5470000002463138
035   $a(OCoLC)952028505
035   $a(OCoLC)995470000002463138
035   $a(EXLCZ)995470000002463138
100   $a20160622d2009      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aBeneficiary utilization of albuterol and levalbuterol under Medicare Part B
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2009.
215   $a1 online resource (iv, 28 pages) $cillustrations
300   $aTitle from title screen (viewed June 17, 2016).
300   $a"August 2009."
300   $a"OEI-03-07-00440."
320   $aIncludes bibliographical references.
517 1 $aBeneficiary utilization of albuterol and levalbuterol under Medicare Part B
606   $aMedicare beneficiaries
606   $aHealth insurance claims$zUnited States$vCode numbers
606   $aAlbuterol
606   $aAsthma$xTreatment$zUnited States$xAuditing
606   $aPharmaceutical policy$zUnited States
615  0$aMedicare beneficiaries.
615  0$aHealth insurance claims
615  0$aAlbuterol.
615  0$aAsthma$xTreatment$xAuditing.
615  0$aPharmaceutical policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707237103321
996   $aBeneficiary utilization of albuterol and levalbuterol under Medicare Part B$93310686
997   $aUNINA